Mechanisms of action of PDE5 inhibition in erectile dysfunction.
about
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsMolecular pathophysiology of priapism: emerging targetsPhosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men.Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaPivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacyFemale sexual dysfunction: therapeutic options and experimental challenges.Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunctionCombination of mesenchymal stem cell injection with icariin for the treatment of diabetes-associated erectile dysfunction.Nitric oxide/redox-based signalling as a therapeutic target for penile disorders.Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor.Comparison of Neuroprotective Effect of Bevacizumab and Sildenafil following Induction of Stroke in a Mouse Model.Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction.Clinical and molecular genetics of the phosphodiesterases (PDEs).Angiotensin-(1-7) Downregulates Diabetes-Induced cGMP Phosphodiesterase Activation in Rat Corpus Cavernosum.Clinical use of sildenafil in pulmonary artery hypertension.Hydrogen sulfide and erectile function: a novel therapeutic target.Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitusNeuroprotective and Nerve Regenerative Approaches for Treatment of Erectile Dysfunction after Cavernous Nerve Injury.Strategies in early clinical development for the treatment of basic defects of cystic fibrosis.The role of cGMP and its signaling pathways in kidney disease.Nitric oxide: what's new to NO?Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.Advances in the understanding of priapism.Potent Phosphodiesterase Inhibition and Nitric Oxide Release Stimulation of Anti-Impotence Thai Medicinal Plants from "MANOSROI III" Database.A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction.Regulation of injury-induced neurogenesis by nitric oxide.An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.Modulation of some markers of erectile dysfunction and malonaldehyde levels in isolated rat penile tissue with unripe and ripe plantain peels: identification of the constituents of the plants using HPLC.In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5.Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?Erectile dysfunctionDownstream Targets of Cyclic Nucleotides in Plants
P2860
Q26800403-D0AB6F9A-72B3-47AB-9E80-32C1202B191DQ27010069-742CA046-F2DF-44FC-A777-B712F7D5B445Q27687631-A0E3476E-36B8-4F4A-AC61-C23A0CA42C2BQ28077954-BEE7B2E5-E239-4952-A61F-C93D054BA6ADQ33552229-40D191FA-2999-4D9F-B2B2-7E9E4B38BB05Q33562863-4E175BBD-4CAB-471C-ACC7-BF9EC9DCCA96Q33916555-41A764AF-F2A6-44B0-B6BD-76AF95CC8CE0Q34112983-F9A851A2-0AE2-413A-9D7B-E98C2FBAADEBQ34129318-314E9497-36A8-4004-93EE-1B9D94226916Q34433634-1BC21E81-D4CC-488A-A680-E92B9AD21F3DQ35545755-16977853-28DD-4FFF-945C-451B959EB9E2Q36325499-21F97267-83EE-4463-B989-B119A66CE4E6Q36481074-F3B11A4F-9DA9-4D7B-93AD-F625387A4713Q36572595-1108749F-A90F-4D78-A040-7B8EF6088F37Q36995042-8910721D-0577-469F-B9AC-CD9E1DA17DD1Q37543075-06C31C37-899C-4F4B-995B-D4E751A089D4Q37657841-72C657B1-C669-4639-B1EB-2675E6762B58Q37680926-1444AD74-162E-497C-8CC2-D1D4E19D41D5Q37729986-302D297F-1173-4A14-98DB-4EA2DC091C37Q37862060-6498C3B6-34BA-4A06-8E4B-5A9DF7DDDDC1Q38466768-417ABBC4-1566-4B89-AEC6-742DA5B7C029Q38640386-BCB0FC9C-FB9E-4906-AA85-F3E8B3972AA8Q38733938-032A196D-AE77-4894-9EB2-15E4EF309EA5Q38896087-247F41CE-2BF6-43BB-9603-CE1DFC50CCB6Q39038560-D3B054A7-AD67-4ABC-B05C-80D8E3AE37ACQ39162370-7F298552-8A55-4E2B-9F0C-202432628F7EQ39327895-93194E84-2B7B-41C6-BD74-81E37EA6257CQ41294140-1B889C55-CFDB-4EE4-9770-3634E1D42EF1Q41945517-DF6D9F06-96D9-4D5C-B90A-87CAEDAC286AQ42041084-688972B0-E1A5-42E7-BC35-E4E9C349BDABQ42693466-C66242D3-41A6-4E89-8081-8381BA4EC6A4Q46936674-906B7ED1-CF91-4D73-8CA2-AA4D37091A8CQ47284635-23290240-5C71-4B92-90A9-7E4B2AF929DAQ47738152-FF1FCD3F-0B9F-4500-9495-FD9D393911DCQ48115926-A8115853-E128-40DF-A72A-FCD041A279CCQ48221143-542242EF-64FD-423C-A9C5-63E7CDB721D7Q50940025-9ADB301E-B0A4-4FE8-BD7B-68BC6FC614D0Q55496270-D402B265-6A44-4606-BDF2-1E6BF3332131Q56966121-3316CCCA-D5C7-4B38-9AC2-ABF0B0A9024AQ57486698-B643EB21-B735-4720-A7A9-EF99DBCB84AF
P2860
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@ast
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@en
type
label
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@ast
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@en
prefLabel
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@ast
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@en
P2860
P356
P1476
Mechanisms of action of PDE5 inhibition in erectile dysfunction.
@en
P2093
P2860
P2888
P356
10.1038/SJ.IJIR.3901205
P478
16 Suppl 1
P577
2004-06-01T00:00:00Z